Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 1 for:    omet | France
Previous Study | Return to List | Next Study

Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC (OMET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03070366
Recruitment Status : Recruiting
First Posted : March 3, 2017
Last Update Posted : March 11, 2022
Information provided by (Responsible Party):
Groupe Oncologie Radiotherapie Tete et Cou

Brief Summary:
The aim of this study is to evaluate the rate of living patients at 1 year with a quality of life criteria (no decrease) and reduced toxicities. This criteria will be compared in both groups., A cost effectiveness study is scheduled also.

Condition or disease Intervention/treatment Phase
Head and Neck Squamous Cell Carcinoma Drug: Chemotherapy Radiation: Stereotactic radiotherapy Phase 2

Detailed Description:

Patients with cancers of aerodigestive tract have metastases limited in their evolution and a pauci-metastatic disease. In these cases, systemic therapy is the standard attitude. However, patients often received chemotherapy in their history and response rates are relatively low. The median survival is between 7 and 11 months with secondary effects and degradation of quality of life. It is a palliative treatment. Data on systemic treatment in the context of a micro-metastatic disease are limited. In contrast, stereotactic irradiation in pauci-metastatic context leads to better local control rates and may sustainedly reduce the progression of metastatic disease.

Stereotactic radiotherapy is increasing use in clinical practice for limited metastatic stages (oligo metastatic with 1-3 synchronized metastases). Radiotherapy in this indication has major advantages and a similar efficacy compared with other ablative treatments.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 78 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Phase II Trial Comparing Chemotherapy Combined With Stereotactic Radiotherapy and Stereotactic Radiotherapy Alone, for Treatment of Oligometastases in Squamous Cell Cancers of the Upper Aerodigestive Tract
Actual Study Start Date : September 21, 2015
Estimated Primary Completion Date : July 2026
Estimated Study Completion Date : August 2026

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Chemotherapy combined with stereotactic radiotherapy (RT)

Chemotherapy is based on patient Performance Status (PS) and comorbidities:

  • PS 0-1: standard treatment: 6 cycles, every 3 weeks cisplatin (100 mg/m² iv on D1), 5FU (4000 mg/m² total dose starting on Day 1 to Day 4 and during 96h in continuous infusion)
  • PS 2/cardiac contra-indication to 5 Fluorouracil (5FU): 6 cycles, every 3-4 weeks cisplatin (100 mg/m² iv on Day 1) or carboplatin Area Under Curve (AUC) 4 or 5 on Day 1 In both case: Cetuximab (loading dose 400 mg/m² iv on Day1, then 250 mg/m² weekly or 500mg/m² every 2 weeks).

Cycle 1 of systemic treatment will be administered before the start of the stereotactic RT. Then, following cycles will be performed after the end of stereotactic irradiation.

Cetuximab maintenance: 250 mg/m² iv weekly. It will be given only if at least disease stabilization is observed at the end of chemotherapy, and will be continued until progression or unacceptable toxicity.

Drug: Chemotherapy
  • cisplatin
  • 5FU
  • carboplatin
  • cetuximab

Radiation: Stereotactic radiotherapy
Stereotactic radiotherapy

Experimental: stereotactic radiotherapy
Splitting will be based on the tumor diameter, and proximity of organs at risk which constitutes any limiting toxicities. It will be 3 or 5 fractions based on the recommendations (CARO-Stereotactic Body Radiation Therapy (SBRT) 2012) and for the purpose of harmonization practices. The prescription dose is 3 x 10 = 30 Gy 3 x 11 = 33 Gy or 3 x 15 = 45 Gy (if 3 fractions) with the possibility of 3 x 20 Gy to the peripheral lung nodules with tracking in Cyberknife or 5 x 7 = 35 Gy or 5 Gy x 10 = 50 (if 5 fractions). Beyond 3 cm of tumor diameter and / or to a distance of less than 1 cm from the GTV in an organ critical risk (eg spinal cord), a splitting up into 5 sessions must be privileged.
Radiation: Stereotactic radiotherapy
Stereotactic radiotherapy

Primary Outcome Measures :
  1. Overall Survival without quality of life deterioration [ Time Frame: 1 year ]
    Overall Survival rate without definitive deterioration of quality of life (by QLQC30) measured at 1 year post treatment

Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: 1 year ]
  2. Progression free survival [ Time Frame: through study completion, an average of 1 year ]
  3. Number of participants with adverse events grade 3 as assessed by CTCAE v4.0 within the first 6 months of treatment [ Time Frame: up to 6 months ]
    Toxicity of grade > or equal to 3, occurring within the first 6 months of treatment

  4. Number of participants with treatment related adverse events as assessed by CTCAE v4.0 [ Time Frame: through study completion, an average of 1 year ]
  5. Overall response rate [ Time Frame: through study completion, an average of 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 77 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥ 18 years
  • PS:0-2
  • Estimated life expectancy ≥ 6 months
  • Histologically confirmed diagnosis of squamous cell carcinoma of the head and neck
  • Target metastases can be treated in stereotactic radiotherapy
  • 1-3 synchronized metastases with unrestricted anatomic site
  • Greater cumulative diameter of synchronous metastases in once organ (liver, lung or brain) ≤ 6 cm with GTV = Clinical Target Volume (CTV)
  • Global maximum diameter (GTV) allowed for pulmonary oligometastases (less than 2 cm from the mediastinum), brain, node, is ≤ 3cm
  • Implementation of a method for taking into account movements and uncertainties (IGRT) for limiting the margin of CTV to PTV (PTV) so as not to exceed 7 cm large cumulative diameter of PTV
  • Performing a positron emission tomography with 18F-2-fluoro-2-deoxy-D-glucose (FDG-PET) 4 weeks before the inclusion
  • In case of cerebral metastases, MRI diagnostic is required
  • If locoregional disease is treated, controlled and non-progressive for more than three months (+/- 4 weeks) at baseline, synchronized initial tumor is possible
  • If metachronous metastases, locoregional disease previously treated should be monitored and considered not progressive for more than three months at baseline
  • In case of prior cancer other than HNSCC, complete remission for over 5 years is possible, any biopsy of metastases is left to the appreciation of referring physician
  • No chemotherapy or local treatment of metastases in the previous 6 months
  • Laboratory tests consistent with the achievement of chemotherapy: Leukocytes> 3,000 / mm3 (including polynuclear> 2000 / mm3) platelets> 150,000 / mm3, serum glutamate oxaloacetate transminase (SGOT), serum glutamate pyruvate transaminase (SGPT), alkaline phosphatase, bilirubin <2.5 upper limit of normal (ULN)
  • Affiliation to an health insurance
  • Informed Consent Form signed

Exclusion Criteria:

  • Concomitant participation in other interventional clinical trial within 4 weeks before inclusion
  • Other prior ablative treatment of targets metastases (surgery, radio frequency) in the previous six months
  • metachronous primitive tumor (second cancer) uncontrolled.
  • contraindication to any systemic therapy (chemotherapy and / or targeted therapy)
  • Known hypersensitivity reaction to 5FU, cisplatin, carboplatin, platin or cetuximab
  • Active infection (infection requiring IV antibiotics), including active tuberculosis and known and declared human immunodeficiency virus (HIV)
  • Other malignancies within 5 years prior to randomization, with the exception of adequately treated basal skin cancer and carcinoma in situ of the cervix
  • Individual deprived of liberty by judicial or administrative decision, or under any kind of guardianship
  • Pregnant or breast feeding women. Every woman who has childbearing potential, must have a negative pregnancy test (serum or urine) within 14 days previous treatment. Patients (men or women) must use a reliable method of contraception throughout treatment and for at least 6 months after discontinuation of chemotherapy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03070366

Layout table for location contacts
Contact: Juliette THARIAT, Pr (0)6 45 53 98 01 ext +33
Contact: Xu Shan SUN, MD (0)3 81 98 88 68 ext +33

Layout table for location information
Hôpital Nord Franche Comté Recruiting
Montbéliard, France, 25209
Contact: Xu Shan SUN, MD    (0)3 81 98 88 68 ext +33   
Sponsors and Collaborators
Groupe Oncologie Radiotherapie Tete et Cou
Layout table for additonal information
Responsible Party: Groupe Oncologie Radiotherapie Tete et Cou Identifier: NCT03070366    
Other Study ID Numbers: GORTEC 2014-04
First Posted: March 3, 2017    Key Record Dates
Last Update Posted: March 11, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The Data Monitoring Committee will meet every year either by a physical meeting or by conference call. Data on the recruitment, toxicity and autonomy are submitted every year.
Keywords provided by Groupe Oncologie Radiotherapie Tete et Cou:
stereotactic irradiation
Additional relevant MeSH terms:
Layout table for MeSH terms
Squamous Cell Carcinoma of Head and Neck
Carcinoma, Squamous Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Head and Neck Neoplasms
Neoplasms by Site